CD21, technical only
Use
CD21 is a transmembrane receptor present on mature B-cells and follicular dendritic cells that binds the C3d fragment of the complement system as well as Epstein Barr virus (EBV) and HHV8. CD21 antigen has been reported in B-cell chronic lymphocytic leukemias, a subset of T-cell acute lymphocytic leukemias, follicular/mantle cell lymphomas, and mature leukemias/lymphomas.
Special Instructions
Not provided.
Limitations
Stated turn-around-times (TATs) are for clinical use only and subject to change based on biopharma protocol requirements. Final TATs will be specified in the biopharma study contract. Specimens must be fixed in 10% NBF or B plus. All other fixatives will be rejected.
Methodology
Immunoassay (IHC)
Biomarkers
CD21
Protein
Result Turnaround Time
2 days
Related Documents
For more information, please review the documents below
Specimen
Tissue (FFPE)
Volume
Not provided
Minimum Volume
Not provided
Collection Instructions
Fixative should be at a 20:1 fixative to tissue ratio, 10% neutral buffered formalin (NBF) for 6-72 hours (48-72 hours PREFERRED).
Storage Instructions
15°C to 25°C
Causes for Rejection
Specimens must be fixed in 10% NBF or B plus. All other fixatives will be rejected.
Stability Requirements
| Temperature | Period |
|---|---|
| Room Temperature | ≤ 72 Hours for Fresh Tissue, Indefinite for FFPE blocks and unstained slides |